

# Obesity III

## Obesogen Assays: Limitations, Strengths, and New Directions



WAYNE STATE  
UNIVERSITY



Center for Urban  
Responses to  
Environmental  
Stressors




Chris Kassotis, PhD  
Assistant Professor  
Wayne State University  
 @cdkassotis

CHE EDC Strategies Partnership Webinar Series  
May 19, 2022


# Overview of Obesogen Models

## Established and Emerging Obesogenic Chemical Evaluation Models

*In vitro* models



*In vivo* models




# Use of Models in Metabolic Health Toxicity Assessments

- Evaluating causal toxicity of chemicals relies on a combination of *in vitro* and *in vivo* models
  - Need for HTP, reliable *in vitro* models to accurately screen for and prioritize higher order testing
  - Need for reliable *in vivo* models that are cost-effective, have high translation to human health, and are well-validated
- Traditionally, MDC research has relied heavily on rodent-based cell and animal models (3T3-L1)
  - Models used have been broadening over time
    - Increasing use of MSCs and human cell models
    - Increasing use of fish models, particularly zebrafish
    - Increasing use of non-traditional models such as fruit fly, c. elegans

# Potential Mechanisms of Metabolic Dysfunction

➤ Numerous potential mechanisms of metabolic disruption:

- Adipose lineage commitment from MSCs
- Adipocyte differentiation from precursor committed cells
  - Increased pre-adipocyte proliferation
  - Increased lipid uptake
- Shifting energy balance to favor calorie storage
- Altering basal metabolic rate
- Altering hormonal control of appetite and satiety
- Altering brain circuitry that controls food intake, energy expenditure




# Adipocyte Differentiation Process

## Adipocyte commitment

Mesenchymal stem cell →



Other pathways:  
Myoblasts  
Osteoblasts  
Chondroblasts



Resemble mature white adipocyte


## Adipocyte differentiation

**Adipoblast**

Pref-1


**Preadipose cell**  
A2COL6/pOb24  
LPLF A transport  
PPAR $\delta$

**Preadipose cell**  
C/EBP  $\beta/\delta$   
IGF-1  
PRAR  $\gamma_2$




**Immature adipose cell**

C/EBP  $\gamma$ ; GLUT4;  
 $\beta_2$  AR;  $\beta_3$  AR; ACC  
FAS; ME; ATP-citrate  
lyase; GPDH; HSL;  
ALBP; perilipin; apoE;  
low Km PDE; GPAT;  
LPAT; DGAT; SCDI




Resemble brown/developing white adipose cell




# 3T3-L1 Pre-adipocyte Adipogenesis Assay

- Swiss albino mouse embryonic fibroblast cell line – committed pre-adipocytes
- Extensively used over decades to evaluate adipogenesis
  - Mechanisms of adipocyte differentiation well understood
  - This assay has proven to be a reliable *in vitro* model for screening metabolic disruption *in vivo*.




# Adipogenesis Assay Measures

- Triglyceride accumulation
  - AdipoRed - hydrophilic fluorescent dye
    - Partitions into lipid droplets in the cell




(A)



(B)


- Cell proliferation/cytotoxicity
  - NucBlue DNA dye (Hoechst 33342)
    - Partitions into nuclei and fluoresces under blue light



# Diversity of Cell Model Utilization


*In vitro* models for metabolic disruption screening

## ADIPOCYTES




- **Preadipocytes**
  - Proliferation
  - Adipogenesis
- **Mesenchymal Stem cells**
  - Characterization of Obesogens
- **Spheroid adipocyte model**
  - Adipose physiology

## LIVER



- **HepaRG**
  - Aldolase B, CYP2E1, CYB3A4
  - CYP1A1, CYP1A2, CYP1B1
- **Primary Human Hepatocyte**
  - Drug metabolism
  - Liver enzyme induction
- **3D cell culture**
  - NASH model

## MUSCLE




- **C2C12**
  - Insulin signaling
  - Mitochondrial function
  - Protein synthesis
- **L6**
  - IR expression
  - Glucose uptake
  - Insulin Resistance
- **Primary Myoblast**
  - Calcium signaling
  - Resting potential

# Growing Reliance on MSCs, Human Cells


- Increasing commercial availability of human MSCs, human pre-adipocytes
  - Less reliance on donors, self-isolation
  - Can source from males/females, lean/obese, diabetic/non, subcutaneous/visceral, etc.
- Ability to examine the interplay of commitment across cell lineages (e.g., bone and adipose, muscle, etc.)
- Increasing utility of liver cell assays to examine TAFLD/NAFLD phenotypes, primary human hepatocytes (despite limitations) have increasing use in drug metabolism
- Limited but increasing evaluation of myogenic differentiation and ability of MDCs to suppress signaling/development

# Examination of Adipocyte Lineage Commitment as More Novel Endpoint

## Commitment assays



## Adipogenesis assays



### Assay endpoints:

Triglyceride accumulation (Nile Red stain)

Pre-adipocyte proliferation (Hoescht DNA stain)

Adipocyte lineage commitment (comparison of triglyceride accumulation between exposure study designs)

# Increasing Diversity of *in vivo* Models


## *In vivo* models for metabolic disruption screening

Models	Advantages	Disadvantages
<b>Zebrafish</b> 	<ul style="list-style-type: none"> <li>• Rapid development, ease of breeding, transparency</li> <li>• Metabolic organs/tissues are physiologically and anatomically similar to humans</li> <li>• High-resolution fluorescent imaging of total body adipose</li> <li>• Ease of molecular manipulation, wealth of transgenic models</li> </ul>	<ul style="list-style-type: none"> <li>• Moderate flexibility</li> <li>• Moderate translational value</li> </ul>
<b>Medaka</b> 	<ul style="list-style-type: none"> <li>• Genetic sex determination like humans</li> <li>• Rapid development, ease of breeding, transparency</li> <li>• Metabolic organs/tissues are physiologically and anatomically similar to humans</li> <li>• Ease of molecular manipulation, small genome size, high diversity</li> </ul>	<ul style="list-style-type: none"> <li>• Moderate flexibility</li> <li>• Moderate translational value</li> <li>• Less characterization of adipose relative to zebrafish</li> </ul>
<b><i>C. elegans</i></b> 	<ul style="list-style-type: none"> <li>• Compounds that modulate fat storage and obesity can be identified</li> <li>• Food intake and energy expenditure can be measured easily</li> <li>• Less regulations governing invertebrate animal use</li> </ul>	<ul style="list-style-type: none"> <li>• Lower conservation of biological pathways with mammals</li> <li>• Lack of specific organs and circulatory systems</li> </ul>
<b><i>D. melanogaster</i></b> 	<ul style="list-style-type: none"> <li>• Small size, short generation time, inexpensive and easy breeding</li> <li>• Several discrete organs perform the same as humans</li> <li>• Less regulations governing invertebrate animal use</li> </ul>	<ul style="list-style-type: none"> <li>• Anatomically different from mammals</li> <li>• Lower conservation of many relevant biological pathways with mammals</li> </ul>
<b>Rodents</b> 	<ul style="list-style-type: none"> <li>• Well described model with clear translation to human outcomes</li> <li>• Periconception, pregnancy, parental and offspring, short- and long-term, multi- and trans-generational outcomes can be assessed</li> <li>• Diverse housing materials readily available</li> <li>• Well-characterized &amp; customizable feed options readily available</li> <li>• Inbred and outbred models available to dissect role of genes, environment, and their interactions</li> </ul>	<ul style="list-style-type: none"> <li>• Time consuming and expensive compared to above alternatives, but less so with larger animal models (e.g. porcine, bovine, ovine, and non-human primates).</li> <li>• Ethical issues; regulatory push to reduce use of mammalian vertebrate animal models</li> </ul>




# Zebrafish as a Metabolic Model

- Measurable adipose/adipocytes appear as early as ~9-12 days of development in zebrafish, originally in the pancreatic and abdominal visceral depots
- 34 anatomically/physiologically/molecularly distinct adipose depots throughout the body of the fish
  - Clear developmental timeline
- Fish adipose tissue contains a heterogeneous cell population, including adipocyte progenitor cells – similar to mammals
  - Depots separated into subcutaneous, visceral, intramuscular adipose tissues, with characteristics similar to humans
  - Zebrafish do not have brown adipocyte tissue



# Zebrafish as a Metabolic Model

- Molecular mechanisms underlying adipocyte and lipid depot development are highly conserved across vertebrates:
  - Genes associated with adipocyte differentiation (*fabp*, *pparg*, *cebpa*), lipolysis (*lipoprotein lipase*), and endocrine function (*leptin*, *adiponectin*, *adipsin*)
  - Energy storage functions and morphology of adipose tissue
- Adipose depots respond to high fat challenge and food withdrawal as you would anticipate
  - organisms utilize the adipose in times of food stress and pack on extra adipose with HFD
- Imaging of whole-animal adipose in mammals is limited, technically challenging, and generally low resolution, whereas imaging in fish is high-resolution and relatively easy



# *C. Elegans* as a Metabolic Model

- Small nematode living in temperate soil environments
- Main regulatory pathways of energy homeostasis shared with mammals
  - Lower conservation of many of these pathways and lack of specific organs
    - Lack PPAR $\gamma$ , though express orthologs to PPAR $\alpha$  and PPAR $\delta$
    - No identifiable homolog for leptin
    - No cells specifically designed for lipid storage (i.e., adipocytes)
    - Store lipids primarily in intestinal and epidermal skin-like cells
- BPS, methylmercury, and other MDCs increase lipid deposition, similar to other *in vivo* MDC models



# *Drosophila melanogaster* as a Metabolic Model

- Fruit fly model organism prized for rapid life cycle, large number of offspring per generation, and simpler genetics relative to most vertebrates
- Despite anatomical differences, lots of functional overlap with humans
  - Fat body covers many of the metabolic health functions of both liver and adipose tissue
- DEHP, methylmercury, PFAS have been described to increase weight/adiposity and/or signaling



# The Future of Obesogen / MDC Screening

- Need for new/improved standardized testing methods to ID chemicals that disrupt metabolic health through diverse mechanisms.
  - Multiple large-scale EU efforts designed to help address this gap
- Improved understanding and validation of alternative / emerging *in vitro* and *in vivo* obesogen models.
  - Increasing use of other animal models, human *in vitro* models, and 3D/spheroid cell culture techniques
- Predictive modeling may offer some improved utility in screening the myriad chemicals in commerce for MDC properties
  - Need for reliable, reproducible ToxCast and other input data
  - Need for robust understanding of MIEs, contributory mechanisms

# Questions?

